A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering ... FDA priority review, comes after more than ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

Spravato, which is derived from ketamine ... patients need to be treated in a doctor’s office or hospital setting and remain in the clinic until the side effects have passed. The nasal spray ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is ... According to US researchers, patients eligible for the Spravato spray include adults with depression who ...